A prospective randomized controlled trial of selective DEB-epiDOX vs. selective conventional TACE for hepatocellular carcinoma focusing on local complete response rate
- Conditions
- Patients with hepatocellular carcinoma who are scheduled to receive selective TACE
- Registration Number
- JPRN-UMIN000021250
- Lead Sponsor
- Japan Interventional Radiology In Oncology Study Group(JIVROSG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 440
Not provided
1. Tumor thrombosis in portal vein 2. Extrahepatic metastasis 3. Ruptured HCC nodules in which TACE is planned 4. Extrahepatic feeding arteries for HCC nodules in which TACE is planned 5. Prior surgical reconstruction or endoscopic treatment of the biliary tract 6. Clinically significant refractory ascites or pleural effusion 7. Severe arterio-portal or arterio-venous shunts in the liver 8. Allergy to contrast medium that precludes angiography 9. Previously registered patients in this study 10. Severe, active co-morbidity 11. Pregnancy, nursing women, or women of childbearing potential, and men who are sexually active and not willing or able to use medically acceptable forms of contraception 12. Not eligible because of safety issues judged by investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method